

Special Issue

The Role of Genetic and Epigenetic Aberrations in Cancer

Message from the Guest Editor

In recent decades, the combination of various high-throughput technologies and functional studies have identified and validated signaling pathways that are dysregulated in certain tumor types. Oncogenic mutations, genetic rearrangements, and epigenetic alterations leading to remodeled transcriptional activity and altered protein expression contribute to the malignant behavior of tumor cells. Genome-wide profiles of different tumor entities have revealed that similar mutations originally attributed to only one entity are also present in tumors at other anatomical sites. The identification of biomarkers and therapeutic targets have shown unprecedented efficacy in some cancers and marginal success in others. Thus, identifying patient subgroups that respond to molecular targeted therapies and elucidating primary resistance mechanisms by integrating molecular profiling and histopathological characteristics are important components to increase treatment efficacy and provide more precise therapeutic options.

Guest Editor

Dr. Matthias Wirth

Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, 12203 Berlin, Germany

Deadline for manuscript submissions

closed (16 November 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/104414

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)